An innovative research effort has found that providing pluripotent cells to fetuses diagnosed with spina bifida as part of a surgical repair can be a "important advancement" in managing prenatal disorders.
Study Parameters and Security
The research conducted in the United States involved six unborn babies with myelomeningocele. Doctors administered mother's placental stem cells directly onto the baby's spinal cord during the repair procedure.
Critically, the stem cell application demonstrated a favorable safety profile. Researchers confirmed that the cells did not cause tumors, disrupt the healing process, or block the correction of related neurological issues.
Promising Outcomes
Post-birth MRI scans showed a successful correction of hindbrain herniation in all six infants. This neurological improvement is strongly associated with improved motor skills and quality of life.
"Should it enable a greater number of infants able to walk who wouldn't have, it could establish itself as their standard of care," said the lead researcher. "The results are super exciting and open the door to a variety of prospective innovative interventions."
Future Implications and Hope
Commentators reviewing the findings proposed that subsequent studies of these noted improvements could announce a "different age" in in-utero treatment. The potential to improve neurological damage seen in utero is considered a paradigm-shifting aim.
Notably important would be better management of continence and digestive health, which are common challenges for those diagnosed with this defect.
Looking Ahead
Despite this being a first-in-human effort was small in scale, its established security and encouraging indicators offer a robust platform for broader investigative efforts. The integration of stem cell therapy with proven prenatal surgical methods holds considerable promise for transforming outcomes for babies yet to be born with this neural tube defect.